Brief: Verrica Pharma Announces Preliminary Topline Results From Part 2 Of Phase 2 Clinical Study Of VP-315

Verrica Pharmaceuticals

14/08/2024 12:47

Aug 14 (Reuters) - Verrica Pharmaceuticals Inc  VRCA.O :
    * VERRICA PHARMACEUTICALS ANNOUNCES POSITIVE PRELIMINARY
TOPLINE
RESULTS FROM PART 2 OF PHASE 2 CLINICAL STUDY OF VP-315, AN
INVESTIGATIONAL ONCOLYTIC PEPTIDE-BASED IMMUNOTHERAPY FOR THE
TREATMENT OF PATIENTS WITH BASAL CELL CARCINOMA
    * 51% OF LESIONS TREATED IN PART 2 ACHIEVED COMPLETE
HISTOLOGICAL
CLEARANCE
    * VP-315 IS WELL TOLERATED WITH NO TREATMENT-RELATED SERIOUS
ADVERSE EVENTS
    * NO DOSE-LIMITING TOXICITIES OR SERIOUS ADVERSE EVENTS
REPORTED
    * EXPECTS GENOMIC AND T-CELL (IMMUNE RESPONSE) DATA IN Q1 OF
2025
    * PLANS TO REQUEST END-OF-PHASE 2 MEETING WITH FDA IN H1
2025

Source text for Eikon:  ID:nGNX1QW5Lk 
Further company coverage:  VRCA.O 

 ((Reuters.Briefs@thomsonreuters.com;))